Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Clinical trial NCT07623681 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07623681
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-10
- Primary completion
- 2026-06-30
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.